This data comes from the company’s Phase 2b/3 Pruritus Relief through Itch-Scratch Modulation (PRISM) trial. That trial was testing the use of Haduvio to treat prurigo nodularis. This is an inflammatory skin disease that causes extremely itchy rashes.
Trevi Therapeutics notes that 25% patients taking Haduvio met the study’s primary endpoint, as compared to 14% from the placebo group. Haduvio patients also saw a significant improvement in “ItchyQoL” compared to placebo. 55% of Haduvio patients also saw at least a 1-category improvement on the Prurigo Activity Scale compared to 38% of placebo patients.
Jennifer Good, president and CEO of Trevi Therapeutics, said the following about the results in a press release.
This positive trial in prurigo nodularis, along with the highly statistically significant data from the interim analysis of our Phase 2 trial in IPF chronic cough that we presented earlier this year, further supports our belief that Haduvio could potentially benefit patients across a broad range of refractory chronic pruritic and cough conditions.
TRVI stock is also seeing heavy trading this morning following the clinical trial news. This has some 39 million shares on the move as of this writing. That’s well above the company’s’ daily average trading volume of about 706,000 shares.
TRVI stock is up 20.5% as of Wednesday morning.
There’s more recent stock market news for investors to dive into below!
We’ve got all the hottest stock news worth noting on Wednesday! Among that is why shares of monkeypox stocks, Upstart (NASDAQ:UPST), and McCormick (NYSE:MKC) are on the move today. You can learn all about these topics at the following links!
More Wednesday Stock Market News
- Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile
- Upstart (UPST) Stock Drops 10% on Morgan Stanley Downgrade
- MKC Stock Slumps as McCormick Misses on Earnings, Cuts Forecast
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.